Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Fowler

Showing results (361-370 of 398) with videos related to

Pageof 40
Sort By:
Blood Advances|March 31, 2022
SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximabMario L Marques-Piubelli, Edwin R Parra, Lei Feng, et al.
Nature Communications|June 8, 2023
Astrocyte-oligodendrocyte interaction regulates central nervous system regenerationIrene Molina-Gonzalez, Rebecca K Holloway, Zoeb Jiwaji, et al.
Blood Advances|May 1, 2019
Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphomaChelsea C Pinnix, Sarah A Milgrom, Chan Yoon Cheah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2018
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN StudyAjay K Gopal, Stephen J Schuster, Nathan H Fowler, et al.
The Lancet. Oncology|December 3, 2014
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan H Fowler, R Eric Davis, Seema Rawal, et al.
Nature Communications|February 26, 2021
Lentivirus-mediated gene therapy for Fabry diseaseAneal Khan, Dwayne L Barber, Ju Huang, et al.
British Journal of Haematology|December 17, 2016
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphomaDai Chihara, Michelle A Fanale, Roberto N Miranda, et al.
Bone Marrow Transplantation|August 10, 2018
Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patientsAna Zelic Kerep, Jacob Broome, Filip Pirsl, et al.
Blood|February 1, 2012
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantationNancy M Hardy, Vicki Fellowes, Jeremy J Rose, et al.
Blood|May 5, 2022
Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphomaHua-Jay J Cherng, Ryan Sun, Bryant Sugg, et al.
Pageof 40

Showing results (361-370 of 398) with videos related to

Sort By:
Pageof 40
Blood Advances|March 31, 2022
SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximabMario L Marques-Piubelli, Edwin R Parra, Lei Feng, et al.
Nature Communications|June 8, 2023
Astrocyte-oligodendrocyte interaction regulates central nervous system regenerationIrene Molina-Gonzalez, Rebecca K Holloway, Zoeb Jiwaji, et al.
Blood Advances|May 1, 2019
Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphomaChelsea C Pinnix, Sarah A Milgrom, Chan Yoon Cheah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2018
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN StudyAjay K Gopal, Stephen J Schuster, Nathan H Fowler, et al.
The Lancet. Oncology|December 3, 2014
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan H Fowler, R Eric Davis, Seema Rawal, et al.
Nature Communications|February 26, 2021
Lentivirus-mediated gene therapy for Fabry diseaseAneal Khan, Dwayne L Barber, Ju Huang, et al.
British Journal of Haematology|December 17, 2016
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphomaDai Chihara, Michelle A Fanale, Roberto N Miranda, et al.
Bone Marrow Transplantation|August 10, 2018
Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patientsAna Zelic Kerep, Jacob Broome, Filip Pirsl, et al.
Blood|February 1, 2012
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantationNancy M Hardy, Vicki Fellowes, Jeremy J Rose, et al.
Blood|May 5, 2022
Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphomaHua-Jay J Cherng, Ryan Sun, Bryant Sugg, et al.
Pageof 40